Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.12.19
Views: 219
Rating:

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

Dr Jeffrey Lancet speaks to ecancer at the 2019 ASH meeting in Orlando about a phase 1 study looking at the outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3.

He explains that therapy-related AML is a difficult to treat type of secondary AML and is frequently associated with previous chemotherapy exposure.

Dr Lancet reports that for the therapy-related AML patients the overall survival was better with the CPX-351.

Related videos

follow us

WIN 2020


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation